Table 1.
SIRs of all-cancer and cancer types by anatomical site or histology among RA patients with different DMARDs.
| Site | csDMARDs | bDMARDs | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | SIR | 95% CI | p-value | I (2) | N | SIR | 95% CI | p-value | I-square | ||||
| Overall cancer | 13 | 1.15 | (1.09, 1.22) | <0.001 | 79.7% | 9 | 0.91 | (0.72, 1.14) | 0.402 | 82.4% | |||
| Respiratory system | |||||||||||||
| Lung cancer | 11 | 1.77 | (1.50, 2.09) | <0.001 | 72.6% | 5 | 1.20 | (0.84, 1.73) | 0.315 | 52.4% | |||
| Hematological malignancies | |||||||||||||
| Lymphoma | 8 | 2.15 | (1.78, 2.59) | <0.001 | 35.9% | 7 | 4.19 | (2.51, 7.00) | <0.001 | 74.5% | |||
| Non-Hodgkin’s lymphoma | 9 | 2.04 | (1.71, 2.44) | <0.001 | 47.5% | 4 | 2.63 | (1.18, 5.86) | 0.018 | 73.7% | |||
| Hodgkin’s lymphoma | 5 | 3.17 | (2.56, 3.94) | <0.001 | 0.0% | 3 | 6.11 | (2.11, 17.72) | 0.001 | 0.0% | |||
| Leukemia | 4 | 1.96 | (1.18, 3.25) | 0.009 | 69.4% | 1 | 0.75 | (0.04, 15.33) | NA | – | |||
| Multiple myeloma | 2 | 1.94 | (1.36, 2.77) | <0.001 | 0.0% | 1 | 1.68 | (0.42, 6.74) | NA | ||||
| Integumentary system | |||||||||||||
| Non-melanoma skin cancer | 6 | 1.50 | (1.1, 2.06) | 0.011 | 76.0% | 8 | 1.61 | (1.34, 1.94) | <0.001 | 61.7% | |||
| Melanoma | 6 | 1.72 | (1.26, 2.36) | 0.001 | 69.2% | 1 | 1.57 | (0.70, 3.49) | NA | ||||
| Squamous cell carcinoma | 2 | 1.63 | (1.02, 2.60) | 0.041 | 52.8% | 3 | 1.42 | (1.21, 1.66) | <0.001 | 0.0% | |||
| Basal cell carcinoma | 1 | 1.22 | (1.06, 1.40) | 0.005 | 2 | 1.05 | (0.74, 1.49) | 0.788 | 72.0% | ||||
| Reproductive and urinary organs | |||||||||||||
| Breast cancer | 8 | 0.84 | (0.79, 0.91) | <0.001 | 0.0% | 3 | 0.56 | (0.42, 0.74) | <0.001 | 0.0% | |||
| Prostate cancer | 6 | 0.93 | (0.79, 1.10) | 0.426 | 37.6% | 3 | 0.80 | (0.47, 1.36) | 0.405 | 6.2% | |||
| Bladder cancer | 5 | 1.27 | (0.87, 1.86) | 0.212 | 84.1% | 2 | 0.83 | (0.45, 1.53) | 0.545 | 0.0% | |||
| Cervical cancer | 5 | 1.49 | (0.98, 2.28) | 0.064 | 78.0% | 2 | 1.04 | (0.69, 1.58) | 0.845 | 0.0% | |||
| Renal cancer | 4 | 1.36 | (1.05, 1.75) | 0.02 | 63.1% | 2 | 0.98 | (0.63, 1.53) | 0.945 | 0.0% | |||
| Cancer of uterus Endometrial |
4 | 0.53 | (0.40, 0.69) | <0.001 | 20.3% | 2 | 0.48 | (0.30, 0.76) | 0.002 | 0.0% | |||
| ovarian cancer | 2 | 0.85 | (0.31, 2.33) | 0.75 | 88.0% | 2 | 1.48 | (0.79, 2.76) | 0.222 | 26.2% | |||
| Cancer of vulva and vagina | 2 | 2.00 | (0.80, 4.96) | 0.136 | 0.0% | 1 | 0.80 | (0.10, 5.80) | NA | – | |||
| Cancer of testis | 2 | 1.29 | (0.28, 6.05) | 0.745 | 0.0% | – | – | – | – | – | |||
| Cancer of urethra | 1 | 1.12 | (0.54, 2.34) | 0.763 | – | 1 | 1.31 | (0.68, 2.52) | NA | – | |||
| Digestive system | |||||||||||||
| Colorectal cancer | 8 | 0.80 | (0.6, 1.07) | 0.138 | 84.5% | 3 | 0.93 | (0.38, 2.26) | 0.869 | 89.4% | |||
| Gastric cancer | 6 | 1.05 | (0.71, 1.55) | 0.825 | 55.9% | 1 | 0.85 | (0.32, 1.49) | NA | – | |||
| Liver cancer | 4 | 1.13 | (0.93, 1.36) | 0.221 | 0.0% | 1 | 2.10 | (0.50, 8.40) | NA | – | |||
| Pancreas cancer | 3 | 0.90 | (0.73, 1.10) | 0.291 | 0.0% | 2 | 0.65 | (0.26, 1.59) | 0.345 | 34.2% | |||
| Esophageal cancer | 3 | 1.45 | (1.10, 1.90) | 0.007 | 0.0% | 1 | 0.85 | (0.32, 1.49) | NA | – | |||
| Cancer of small intestine | 1 | 1.22 | (0.75, 1.89) | NA | – | – | – | – | – | – | |||
| Gallbladder cancer | 1 | 2.00 | (0.30, 14.40) | NA | – | – | – | – | – | ||||
| Cancer of bile duct | – | – | – | – | – | 1 | 0.69 | (0.30, 1.15) | NA | – | |||
| Anus cancer | – | – | – | – | – | 1 | 2.50 | (0.60, 10.00) | NA | – | |||
| Other malignancies | |||||||||||||
| Cancer of soft tissues | 2 | 1.42 | (1.00, 2.01) | 0.05 | 0.0% | – | – | – | – | – | |||
| Brain and central nervous system cancer | 1 | 1.12 | (0.89, 1.40) | 0.327 | – | 2 | 0.81 | (0.12, 5.22) | 0.821 | 65.9% | |||
| Oral cancer | 1 | 1.12 | (0.68, 1.72) | NA | – | 3 | 1.26 | (0.38, 4.19) | 0.705 | 67.3% | |||
| Head and neck cancer | 1 | 0.30 | (0.20, 0.70) | <0.001 | – | – | – | – | – | – | |||
| Cancer of bones and joints | 1 | 5.70 | (2.16, 15.03) | <0.001 | – | – | – | – | – | ||||
| Cancer of larynx | 1 | 1.19 | (0.63, 2.04) | – | – | – | – | – | – | – | |||
| Thyroid cancer | – | – | – | – | – | 1 | 1.32 | (0.53, 2.24) | NA | ||||
An SIR >1 suggests that the cancer risk is higher than that of the ordinary population. SIR, standardized incidence ratio; CI, confidence interval.
N refers to the total number of SIR values of corresponding site-specific cancers in RA patients with different immunosuppressants.